A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study is to determine whether WR279396 with occlusion (a polyurethane dressing)
is more effective than WR279396 without occlusion for once daily treatment.
Extensive objective and subjective local tolerance data will also be captured during this
trial, as well as surrogate markers (parasite loads and aminoglycosides concentration in the
deep dermis) that may help to determine the optimal number and duration of treatments.
The results from this study will help determine the most practical treatment schedule and
will answer questions that are crucial to improve the present treatment regimen with WR279396
which is twice a day for 20 days.
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command